Get the knowledge

You’ve been told you’re in perimenopause. Maybe your GP said it, or a specialist mentioned it in passing, or you’ve read it in a dozen articles that all seem to say the same vague things. And yet — you’re still confused. Because what you’re experiencing doesn’t seem to fit neatly into any of the explanations you’ve been given.

Maybe you’re flooding through a tampon every hour and your periods have become unpredictable and violent — but the articles you’re reading are talking about hot flushes and night sweats, which you don’t really have. Or maybe you do have the hot flushes and the brain fog, but you also tried HRT and it made things worse, not better. Or perhaps you have both sets of symptoms at different times and you can’t make sense of what’s happening inside your body.

Here is the reason you’re confused: perimenopause is not one thing.

It is two distinct biological phases — with different root causes, different hormone behaviour, different dominant symptoms, and different clinical needs. Most doctors, most practitioners, and most information you’ll find online treats perimenopause as a single entity. That single-entity model is why so many women receive the wrong help, why HRT is sometimes prescribed when it doesn’t fit, and why women spend years cycling through interventions that don’t work.

This page is the explanation you haven’t been given. It is also the foundation of everything I do in my practice.

The Two-Phase Model: Why This Changes Everything

The conventional model of perimenopause goes roughly like this: your ovaries start winding down, oestrogen drops, and you get symptoms until your periods stop. Treatment: replace the oestrogen. Done.

That model is incomplete — and its incompleteness is causing harm.

What research and clinical experience both show is that perimenopause has two biologically distinct phases, separated by a hormonal turning point that most practitioners never identify. These two phases have opposite oestrogen dynamics, opposite cycle patterns, and require opposite clinical approaches. Confusing them — or collapsing them into a single “perimenopause” category — produces exactly the kind of failed care that sends women in circles.

Understanding which phase you’re in is the first question any functional medicine approach must answer.

Phase One: Early Perimenopause

What Is Happening in Your Ovaries

Early perimenopause is not primarily about oestrogen going low. That is the misconception at the heart of most treatment failures in this phase.

Early perimenopause is driven by two compounding processes: follicle depletion and ovarian fibrosis. Together they disrupt ovulation — and it is the loss of ovulation, not the loss of oestrogen, that creates the dominant hormonal picture of this phase.

Here is the sequence. Your ovaries have a finite reserve of follicles — the fluid-filled sacs that house your eggs and produce hormones. That reserve declines throughout your life, but as you move through your late thirties and forties, the rate of decline accelerates. As fewer follicles remain, your pituitary gland works harder: it releases more FSH (follicle-stimulating hormone) to recruit a dominant follicle each cycle.

At the same time, a second process is underway. Every ovulation causes a small amount of tissue trauma to the ovarian surface. Over decades of reproductive cycles, this cumulative trauma triggers an inflammatory repair response — the same mechanism behind fibrosis in any tissue. TGF-β (transforming growth factor beta) activates fibroblasts, which differentiate into myofibroblasts and begin laying down collagen. The ovarian cortex gradually stiffens. This is ovarian fibrosis, and its significance in reproductive aging has only recently been properly recognised in the scientific literature.

Stiff, fibrotic ovarian tissue compresses remaining follicles and impairs their ability to respond to FSH signals — a process sometimes described as gonadotropin desensitisation. The follicles are still there, but they have become, in effect, hard of hearing. The brain shouts louder — FSH rises further. But the response remains erratic and inconsistent.

The result: skipped ovulations. Some cycles complete normally. Others do not. When ovulation is skipped, there is no corpus luteum — the temporary glandular structure that forms after ovulation and produces progesterone. No corpus luteum means no progesterone surge in the second half of the cycle.

And this is the defining hormonal picture of early perimenopause: progesterone crashes whilst oestrogen continues to fluctuate at normal or even elevated levels. It is not an oestrogen problem — it is an oestrogen-to-progesterone ratio problem. Oestrogen is not gone. It is unchecked.

What Oestrogen Is Doing

In early perimenopause, oestrogen does not go low — it goes wild. Because follicle recruitment is chaotic, oestrogen production swings dramatically. In a single month, oestrogen may spike to hyper-physiological levels during an aggressive follicular phase, then crash when that follicle fails to complete ovulation. The following cycle may be normal. The one after may spike again.

This is the oestrogen rollercoaster — not a slow decline, but an erratic, unpredictable lurching between extremes.

What FSH Is Doing

FSH behaviour in early perimenopause is equally unstable. Because some cycles recruit and ovulate follicles while others don’t, FSH bounces between normal reproductive-age ranges and post-menopausal ranges from week to week. A single blood test during this phase can show a completely “normal” FSH one month and a dramatically elevated reading the next.

This is why a single FSH measurement during early perimenopause is almost clinically meaningless. It is a snapshot of one week’s follicular activity — it tells you nothing about the overall picture. Women in early perimenopause are frequently told their FSH is “normal” and therefore cannot be perimenopausal. This is a failure of interpretation, not a failure of their biology.

Cycle Pattern in Early Perimenopause

The hallmark cycle change in early perimenopause is variability of 7 or more days from your normal baseline. If your cycle was reliably 28 days and is now ranging from 21 to 35 days, you are in early perimenopause. Periods are still present — often very present — but irregular. Some cycles may be longer, some shorter. Spotting and mid-cycle bleeding may appear.

Symptoms of Early Perimenopause

All of the dominant symptoms of this phase flow from the same root cause: low progesterone relative to oestrogen.

• Heavy, prolonged, or flooding periods — without progesterone to regulate endometrial shedding, the lining builds and then sheds dramatically
• Rage and sudden irritability — progesterone is neurologically calming; its absence creates a hair-trigger emotional state
• Breast tenderness — oestrogen stimulates breast tissue; unopposed oestrogen makes breast tenderness cyclical and pronounced
• Bloating and water retention — oestrogen promotes fluid retention; progesterone counterbalances it; without that balance, bloating dominates
• Menstrual migraines — linked to oestrogen surges and crashes across the cycle
• Anxiety — progesterone modulates GABA receptors, producing a calming effect; its absence amplifies anxiety, particularly in the pre-menstrual week
• Poor sleep — progesterone promotes slow-wave sleep; low progesterone means fragmented, unrefreshing sleep
• Worsening PMS — the perimenstrual phase becomes more pronounced as the progesterone deficit deepens

Why HRT Often Makes Early Perimenopause Worse

This is perhaps the most important clinical insight on this page, and the clearest point of differentiation in how I practice.

Standard HRT — particularly oestrogen-dominant preparations — is designed to address the invented oestrogen deficiency. In early perimenopause, oestrogen is not in decline. It is erratic and unchecked by progesterone. Adding more oestrogen into that environment is adding fuel to an already unstable fire. Many women in early perimenopause who are placed on HRT report that their symptoms worsen — more anxiety, heavier bleeding, more breast tenderness, deeper mood instability. This biology explains it exactly.

Early perimenopause needs a fundamentally different approach: supporting progesterone, addressing the inflammatory drivers of ovarian fibrosis, and reducing oestrogen load — not adding to it.

Phase Two: Late Perimenopause

The Hormonal Turning Point

There comes a point in the perimenopause transition when the follicle supply drops below a critical threshold. The erratic, unpredictable recruitment of those earlier years gives way to a different reality: oestrogen now consistently and persistently declines. The rollercoaster ends. And a new set of challenges begins.

Late perimenopause begins when you start skipping complete menstrual cycles. The clinical marker is a gap of 60 or more days between periods. Once this occurs, you have crossed the threshold — the follicle supply can no longer sustain consistent cycle activity.

FSH, which was bouncing unpredictably in early perimenopause, now begins a steady, non-stop upward climb. It is no longer erratic — it reflects the persistent absence of follicular feedback. This is the FSH pattern that many practitioners recognise as “perimenopausal” or “menopausal” on a blood test, because it is consistent enough to be informative.

What Changes in Late Perimenopause

Oestrogen is now genuinely and consistently low. The follicles that were driving those wild spikes are no longer available in meaningful numbers. For some women, this is initially a relief — the flooding periods ease, the breast tenderness fades, and the violent hormonal surges of early perimenopause begin to settle. But a different and more complex set of changes takes their place.

Falling ovarian oestrogen triggers three biological reorganisations that begin running simultaneously — and understanding them is what makes late perimenopause make sense.

The first is a brain energy crisis.
Oestrogen is not only a reproductive hormone — it is a master regulator of how the brain uses glucose as fuel. When it falls, the brain’s primary energy supply becomes less efficient. This is the neurological root of the symptoms most associated with menopause: the hot flushes (the hypothalamus misfiring on temperature regulation), the brain fog and word-retrieval problems, the anxiety that arrives differently from early perimenopause — driven now by cortisol and adrenaline surges as the body tries to find alternative fuel for the brain. The fatigue, the low mood, the palpitations, the central weight gain — these are all expressions of the same underlying fuel crisis. In my framework, this is The Energy Shift.

The second is an oestrogen handover.
As the ovaries step back, the body does not simply stop making hormones — it relocates production. The adrenal glands supply a precursor hormone called DHEA, and individual tissues — bone, muscle, skin, brain, vagina — begin converting it locally into whatever they each need. This distributed tissue-level system is called intracrine hormone production, and it is the body’s built-in adaptation to ovarian decline. When it works well, it is elegant. When it is under-resourced — through chronic stress, blood sugar instability, or nutritional depletion — the result is joint pain, muscle loss, thinning skin, vaginal dryness, cognitive slowing, and the chin hair and crown thinning that insulin drives through a separate pathway. Critically, these symptoms can appear in late perimenopause while cycles are still occurring — the handover has already begun. In my framework, this is The Oestrogen Shift.

The third is a nervous system reorganisation.
The hormonal architecture that supported the tend-and-befriend stress response — oestrogen and oxytocin — begins withdrawing. The familiar way of coping through connection, smoothing, and accommodation starts to cost more than it returns. You may notice the withdrawal, the difficulty tolerating dynamics that once felt manageable, the rage that is harder to place than the early perimenopause rage. This is not a personality change or a breakdown. It is the first signal of a nervous system that is beginning to reorganise — away from accommodation-based regulation and toward something more autonomous. In my framework, this is The Emotional Shift.

These three processes do not wait neatly for each other. In late perimenopause, many women are managing all three simultaneously — the brain energy crisis, the tissue handover, and the beginning of emotional reorganisation — without anyone having named what is actually happening.

The Symptoms of Late Perimenopause

The dominant symptoms of this phase are distinct from early perimenopause, driven by unsupported oestrogen decline rather than progesterone decline:

• Hot flushes — the hypothalamus loses oestrogen-regulated thermostat control; the body misreads core temperature and triggers heat dissipation
• Night sweats — the same mechanism during sleep, compounding the fatigue cycle
• Brain fog and word-retrieval problems — the brain fuel crisis; reduced glucose metabolism in the prefrontal and hippocampal regions
• Anxiety with a different quality — cortisol and adrenaline surges as the body mobilises alternative brain fuel; distinct from the progesterone-withdrawal anxiety of early perimenopause
• Heart palpitations — oestrogen receptors in cardiac tissue and vascular smooth muscle lose activation
• Fatigue — metabolic inefficiency compounded by disrupted sleep
• Low mood — oestrogen modulates serotonin and dopamine; consistent decline can reduce emotional resilience
• Weight gain, especially abdominal — declining oestrogen shifts fat distribution toward visceral tissue
• Joint pain and stiffness — early sign of the tissue hormone handover; the bone pathway losing its local oestrogen supply
• Muscle loss despite exercise — the muscle-testosterone intracrine pathway becoming under-resourced
• Withdrawal and emotional volatility — the tend-and-befriend system beginning its retreat

As these late perimenopause symptoms emerge, the early perimenopause symptoms typically ease. The flooding periods become lighter and then scarce. The breast tenderness reduces. The progesterone-decline rage settles — not because hormonal health has improved, but because the oestrogen surges driving it are no longer occurring. The signal has changed. The problem has changed. The clinical response must change accordingly.

Menopause and Post-Menopause

Menopause itself is a single point in time, not a phase: it is defined as 12 consecutive months without a period. You are not officially menopausal until that 12-month mark has passed — everything leading up to it is perimenopause.

Once 12 months without a period has been reached, post-menopause begins — and it lasts for the rest of life. The biological processes that started in late perimenopause — the tissue hormone handover and the nervous system reorganisation — continue to develop and deepen. The brain energy crisis, if not addressed, persists and compounds. The DHEA-based intracrine system becomes the body’s primary hormone architecture. And the nervous system completes its move from accommodation-based regulation to agency-based regulation — a shift that, when supported clinically, produces a quality of life and sense of self that many women describe as the clearest and most grounded they have ever felt.

Post-menopause is not the end of the hormonal story. It is a different chapter, with different biology, different needs, and different possibilities.

Phase Comparison at a Glance

Feature	Early Perimenopause	Late Perimenopause
Cycle Pattern	Variable by 7+ days from baseline	Skipped cycles — gaps of 60+ days
Oestrogen Levels	Wildly fluctuating (spikes and crashes)	Consistently and persistently low
FSH Behaviour	Bounces unpredictably week to week	Steady, non-stop upward climb
Primary Bleeding	Heavy, prolonged, flooding	Scanty, rare, or absent
Dominant Symptoms	Heavy periods, rage, breast tenderness, anxiety, worsening PMS	Hot flushes, night sweats, brain fog, fatigue, low mood, palpitations
HRT Response	Often worsens symptoms	More straightforwardly applicable
Root Hormonal Driver	Progesterone decline / oestrogen dominance	Oestrogen decline

The Four Shifts: A Map of the Full Transition

Sandra’s clinical framework organises the entire hormonal transition — from the first erratic cycles of early perimenopause through to post-menopause — into four named biological shifts. Each shift has a distinct hormonal driver, a distinct symptom cluster, and a distinct clinical need. They are not stages on a single continuum; they are four genuinely different physiological states.

Shift	Phase	Hormonal Driver	Primary Symptoms
01 — The Progesterone Shift	Early perimenopause	Progesterone decline / oestrogen dominance from anovulatory cycles	Heavy periods, rage, breast tenderness, worsening PMS, anxiety, poor sleep
02 — The Energy Shift	Late perimenopause	Oestrogen decline → brain bioenergetic crisis	Hot flushes, night sweats, brain fog, fatigue, palpitations, central weight gain
03 — The Oestrogen Shift	Late perimenopause	DHEA-driven intracrine hormone production begins as ovarian output falls	Joint pain, thinning skin, vaginal dryness, muscle loss, cognitive changes, chin hair
04 — The Emotional Shift	Late perimenopause	Testosterone and DHEA become increasingly dominant as oestrogen and oxytocin recede	Rage, withdrawal, identity reorganisation, the emergence of agency-based regulation

This framework is why support in early perimenopause looks completely different from support in late perimenopause and beyond. Applying the same hormonal lens to all four shifts — as conventional medicine often does — produces the wrong answers at every stage. An important clinical point: Shifts 03 and 04 begin emerging in late perimenopause as oestrogen reaches its lowest levels — which means a woman in her late 40s skipping cycles may be experiencing all three of Shifts 02, 03 and 04 simultaneously.

For dedicated coverage of each shift, use the internal navigation at the bottom of this page.

How to Identify Which Phase You’re In

The clearest and most accessible diagnostic tool is also the simplest: your cycle pattern.

Check your cycle first:

• Are your periods still present but irregular — arriving anywhere from 3 weeks to 5 weeks apart, when they used to be predictable? That is early perimenopause territory. The 7-day variability criterion is clinically established: if your cycles are varying by more than 7 days from your baseline, the early menopausal transition has begun.
• Are you skipping entire cycles — gaps of 60 days or more with no period? That is late perimenopause. Once a 60-day gap has occurred, the transition to the late phase has begun.

Then check your symptoms:

• Heavy or flooding periods, breast tenderness, premenstrual rage, anxiety that worsens in the week before your period, poor sleep throughout the cycle? Early perimenopause — progesterone decline is driving this.
• Hot flushes, night sweats, brain fog, fatigue, palpitations, central weight gain? Late perimenopause — oestrogen decline and the brain energy crisis.

An important caveat: both phases can coexist during the transition between them. Some women experience symptoms of both simultaneously — they still have some cyclical symptoms from residual progesterone decline while early vasomotor symptoms are emerging. This overlap window is real, and it is one of the reasons perimenopause can feel so bewildering. The phases are not always perfectly sequential — they blur into each other, which is precisely why precise symptom mapping matters more than any single blood test.

The FSH Staging Timeline

Research from the Study of Women’s Health Across the Nation (SWAN) — one of the most comprehensive longitudinal studies of the menopausal transition ever conducted — has identified four distinct stages in FSH behaviour relative to the final menstrual period (FMP):

Stage 1 — Slow early drift (up to 7 years before FMP): FSH begins to drift upwards, but slowly and without the dramatic fluctuations to come. Cycles are still regular. Most women have no idea anything is changing. FSH values at age 42 average around 8 mIU/mL.

Stage 2 — The rollercoaster (7 to 2 years before FMP): FSH accelerates its rate of change significantly — but erratically. It bounces between normal and elevated ranges from cycle to cycle, reflecting chaotic follicle recruitment. This is early perimenopause. FSH values climb from roughly 15 to 33 mIU/mL across this stage, but the week-to-week variation is dramatic. A single reading tells you almost nothing.

Stage 3 — Acute acceleration (2 years before to 1 year after FMP): The most dramatic hormonal shift in a woman’s reproductive life. FSH climbs sharply and consistently, from approximately 34 mIU/mL to 54 mIU/mL. Oestrogen is now declining in earnest. This is the late perimenopause–early postmenopause transition. The onset of 60-day cycle gaps signals this stage has begun.

Stage 4 — Plateau (1 to 2 years post-FMP): FSH stabilises at a sustained elevated level — typically in the range of 70–90 IU/L — and remains there. The reproductive axis has permanently reorganised.

After this plateau, FSH does gradually decline over subsequent decades — a reduction of perhaps 30–50% from peak values in very late life — but the woman remains postmenopausal throughout.

The critical clinical implication of this staging: because FSH bounces so dramatically in Stages 1 and 2, a single FSH measurement taken during early perimenopause may return a value that looks entirely normal for a reproductive-age woman. This does not mean perimenopause is not occurring. It means the test was taken on a week when FSH happened to be in a trough. Serial measurements, timed appropriately, are meaningfully more informative — but even then, FSH alone is not sufficient to determine which phase of perimenopause you’re in.

The Dual Mechanism: Why Some Women Have a Much Harder Perimenopause

This is the question that my clinical model is built around: why do some women sail through perimenopause with manageable symptoms, while others experience years of debilitating hormonal chaos?

Part of the answer lies in the dual mechanism driving early perimenopause: follicle depletion and ovarian fibrosis working together.

Follicle depletion is the primary driver. Fewer eggs mean fewer follicles available for recruitment each cycle, which means more erratic hormonal output. This much is broadly understood.

But ovarian fibrosis — the progressive stiffening of the ovarian cortex through collagen deposition — acts as a compounding accelerator. Here is the mechanism: repeated ovulations over decades of reproductive life cause cumulative microtrauma to the ovarian surface. This triggers an inflammaging response — the same chronic, low-grade inflammatory pathway that underlies tissue aging throughout the body. TGF-β activates fibroblasts into myofibroblasts, which deposit collagen into the ovarian stroma. The cortex stiffens.

A stiffer ovarian cortex physically compresses remaining follicles. Compressed follicles become less sensitive to FSH signals — this is gonadotropin desensitisation. The pituitary, receiving weak feedback from these increasingly unresponsive follicles, responds by producing even more FSH. But more FSH cannot compensate for follicles that cannot hear it. The result: more erratic recruitment, more skipped ovulations, more progesterone crashes, more oestrogen swings.

Fewer follicles and deafer follicles multiply each other’s effect. The combined disruption is greater than either would produce alone.

What accelerates fibrosis — and therefore accelerates and amplifies early perimenopause:

• Insulin resistance and obesity — activate the NLRP3 inflammasome pathway, driving greater TGF-β signalling and faster collagen deposition in ovarian tissue
• Chronic stress and sustained cortisol elevation — suppresses matrix metalloproteinases (the enzymes responsible for collagen turnover), prevents collagen from being broken down, and causes granulosa cell apoptosis that impairs follicle development
• Endometriosis — ovarian endometriomas cause direct iron overload–mediated oxidative stress and fibrotic remodelling within the ovary
• PCOS — the chronic low-grade inflammation characteristic of PCOS accelerates stromal fibrosis independent of ovulatory disturbance
• Smoking — a well-documented accelerant of follicle depletion and ovarian aging
• Endocrine-disrupting chemicals (EDCs) — impair FSH receptor signalling and contribute to ovarian inflammatory burden
• Nutrient deficiencies — particularly Vitamin D (anti-fibrotic through TGF-β inhibition), antioxidants, zinc, and magnesium (all required for granulosa cell function and anti-inflammatory pathways)

If you have insulin resistance, have lived with chronic stress for years, have endometriosis or PCOS, or have significant nutrient gaps, you are likely to experience earlier and more severe early perimenopause. This is not bad luck — it is a biological mechanism that can be understood and addressed.

Where to Go From Here

Understanding which shift you’re in is the starting point for everything else. From here, the four pathways diverge:

If your symptoms are heavy periods, rage, breast tenderness, worsening PMS — cycles irregular but present:
→ Early Perimenopause — The Progesterone Shift →

If your symptoms are hot flushes, night sweats, brain fog, fatigue — skipping entire cycles:
→ Late Perimenopause — The Energy Shift →

If you are post-menopausal with joint pain, thinning skin, vaginal dryness, muscle loss, chin hair:
→ Post-Menopause — The Oestrogen Shift →

If you are experiencing the anger, withdrawal, and identity shift of menopause:
→ The Emotional Shift — From Belonging to Becoming →

Not sure which shift fits? Want objective testing:
→ How to Test Where You Are →

Not Sure Which Phase You’re In?

If you’ve read this page and you’re still uncertain — or if you have symptoms from both columns and don’t know what to make of it — that is exactly the kind of clinical complexity I work with every day.

A one-hour assessment with me will map your symptom pattern, review your cycle history, interpret any existing test results in the context of the four-shift model, and give you a clear picture of where you are and what your next step should be.

Book a consultation →

References

1. Sowers MF, Zheng H, McConnell D, Nan B, Harlow S, Randolph JF Jr. Follicle stimulating hormone and its rate of change in defining menopause transition stages. J Clin Endocrinol Metab. 2008;93(10):3958–3964. doi:10.1210/jc.2008-0482
2. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012;19(4):387–395. doi:10.1097/gme.0b013e31824d8f40
3. Randolph JF Jr, Zheng H, Sowers M, et al. Change in follicle-stimulating hormone and estradiol across the menopausal transition: effect of age at the final menstrual period. J Clin Endocrinol Metab. 2011;96(3):746–754. doi:10.1210/jc.2010-1746
4. Gu M, Yu Y, Wang Y. Ovarian fibrosis: molecular mechanisms and potential therapeutic targets. J Ovarian Res. 2024;17(1):134. doi:10.1186/s13048-024-01448-7
5. Morimoto A, Andreas E, Williams EJ, et al. Female reproductive life span is extended by targeted removal of fibrotic collagen from the mouse ovary. Sci Adv. 2022;8(24):eabn4564. doi:10.1126/sciadv.abn4564
6. Duncan FE, Briley SM, Jasti S, et al. Reproductive age-associated fibrosis in the stroma of the mammalian ovary. Reproduction. 2016;152(3):245–260. doi:10.1530/REP-16-0129
7. Shirafuji A, Tamamura C, Tsuyoshi H, et al. Chronic low-grade inflammation and ovarian dysfunction in women with polycystic ovarian syndrome, endometriosis, and aging. Front Endocrinol. 2023;14:1324429. doi:10.3389/fendo.2023.1324429
8. Trumble BC, Holman DJ, Brindle E, et al. Progesterone and ovulation across stages of the transition to menopause. Menopause. 2010;17(6):1183–1192. doi:10.1097/gme.0b013e3181aa192d
9. Rettberg JR, Yao J, Brinton RD. Estrogen: a master regulator of bioenergetic systems in the brain and body. Front Neuroendocrinol. 2014;35(1):8–30. doi:10.1016/j.yfrne.2013.08.001
10. Brinton RD, Yao J, Yin F, et al. Perimenopause as a neurological transition state. Nat Rev Endocrinol. 2015;11(7):393–405. doi:10.1038/nrendo.2015.82
11. Johnson BW, Duncan FE, Kelsh J, et al. Fibroinflammatory signatures increase with age in the human ovary and follicular fluid. Int J Mol Sci. 2021;22(9):4902. doi:10.3390/ijms22094902
12. Karvonen-Gutierrez C, Greendale GA, Matthews K, et al. The menopause transition and women’s health at midlife: a progress report from the Study of Women’s Health Across the Nation (SWAN). Menopause. 2019;26(10):1213–1227. doi:10.1097/GME.0000000000001424